ITCC-P4 has reached an important milestone: since launching its activities, the platform has received 100 external inquiries from academic…

Every child with cancer deserves access to effective treatments. This Childhood Cancer Awareness Month, we highlight the importance of connecting…

The main publication from the ITCC-P4 consortium showcases a collaborative resource to advance drug development for children and adolescents with…

ITCC-P4 has submitted a joint response to EMA’s public consultation on proof-of-concept data for the development of anticancer medicines in children,…

Developing new treatments for childhood cancers requires models that reflect the diseases researchers aim to treat. ITCC-P4 is working to broaden its…

Selecting relevant tumour models starts with understanding their biology. ITCC-P4 combines molecular characterisation with paediatric oncology…

A COG analysis shows how collaborative trial structures contribute to approved treatments for children with cancer.

Published compromise texts set out a change with particular relevance to paediatric oncology.

EMA’s review of its stepwise PIP pilot highlights an approach to managing uncertainty in early development.

A look back at the December 2025 agreement and its significance for paediatric drug development.